Dr. Martin Graham, PhD Chief Executive Officer, is the Founder of KinderPharm and PKPD Bioscience. He is a graduate of Leeds University, UK (Pharmacology and Microbiology BSc, Joint Honors) and obtained his PhD from the University of London (Institute and Cancer Research, Royal Marsden Hospital, London UK). He conducted post-doctoral research in anti-cancer drug development at the Beatson Institute (University of Glasgow) before joining Sterling-Winthrop Pharmaceuticals (now Sanofi-Aventis) in both the UK and the US. He has held positions of increasing responsibility during his career and was Director of Pharmacokinetics at Centocor Corporation (Johnson and Johnson), and VP of Research and Development, and Regulatory Affairs at Gemin X Biotechnologies and TetraLogic Pharmaceuticals before founding PKPD Bioscience in 2004. Dr Graham has extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA and has been involved in numerous regulatory filings in the US, Japan and Europe for a wide variety of products including Oxaliplatin, Rasburicase, Mitoguazone, Tirapazamine, Alfuzosin, Remicade, and Stelara. Dr. Graham is an Honorary Professor of Pharmacokinetics and Pharmacodynamics at the University of Bradford, Yorkshire, UK and is specialist in PK/PD modeling clinical trial simulation with expertise in pediatric drug development.